オブシディアン・セラピューティクス
OBX
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
| 期間 | EPS | 売上 | FCF |
|---|---|---|---|
| 2026 Q3 | -1.23 | $0 | -$37M |
| 2026 Q2 | -237.20 | $0 | -$25M |
| 2026 Q1 | -0.32 | $0 | -$22M |
| 2025 Q4 | 405.14 | $0 | — |